Target and non-target vessel related events at 10 years post percutaneous coronary intervention

[1]  M. Andía,et al.  Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Schunkert,et al.  10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. , 2020, Journal of the American College of Cardiology.

[3]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[4]  P. Serruys,et al.  Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  David L. Brown,et al.  Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint , 2017, Journal of the American Heart Association.

[6]  A. Yeung,et al.  Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  H. Suryapranata,et al.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients , 2014, Open Heart.

[8]  M. Pfisterer,et al.  Coronary artery disease progression late after successful stent implantation. , 2012, Journal of the American College of Cardiology.

[9]  Seung‐Jung Park,et al.  Contemporary Reviews in Cardiovascular Medicine Paradigm Shift to Functional Angioplasty New Insights for Fractional Flow Reserve- and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention , 2011 .

[10]  A. Kastrati,et al.  Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. , 2011, Circulation.

[11]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[12]  A. Kastrati,et al.  Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.

[13]  M. Joner,et al.  Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.

[14]  M. Leon,et al.  Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. , 2009, JACC. Cardiovascular interventions.

[15]  V. Novack,et al.  Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. , 2009, JACC. Cardiovascular interventions.

[16]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[17]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[18]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[19]  D. Baim,et al.  Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.

[20]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.